Nikos Maniadakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Nikos Maniadakis has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Georgia Kourlaba
The Stavros Niarchos Foundation – Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), First and Second Departments of Pediatrics, National and Kapodistrian University of Athens School of Medicine, Athens, Greece
5 shared publications- Georgia Kourlaba
National and Kapodistrian University of Athens, Greece
5 shared publications Fotini Gialama
Department of Health Services Management, National School of Public Health, 196 Alexandras Avenue; 115 21 Athens, Greece
4 shared publications- Georgia Kourlaba
The Stavros Niarchos Foundation-Collaborative Center for Clinical Epidemiology and Outcomes Research (CLEO), National and Kapodistrian University of Athens, School of Medicine, Athens, Greece.
4 shared publications Panagiotis Prezerakos
Department of Nursing Studies, University of Peloponnese, Efstathiou & Stamatikis Valioti and Plateon, 23100 Sparti, Greece
3 shared publications- Charalampos Tzanetakos
Department of Health Services Organization and Management, National School of Public Health, 196 Alexandras Avenue, 11521, Athens, Greece.
2 shared publications
Latest Publications
- Open Access
- 11 March 2020
- Published by IntechOpen
Weighing Price and Performance for Decisions for Multisource Pharmaceutical Bidding in Public Hospitals in Thailand
Following a national law introduced in 2017 in Thailand, the selection of winning bidders for multisourced pharmaceuticals and medical supplies in public hospitals must reflect “price-performance” aligned with the principles of worthiness, transparency, efficiency, effectiveness and accountability. We describe how a practical tool using Multiple Criteria Decision Analysis (MCDA) for evidence-based decision making in hospital bidding (tender) was developed through a multi-stakeholder workshop format. The local leader of the initiative together with 2 international advisors guided the 37 workshop participants through five interactive steps for local adaptation of the previously developed and validated global MCDA-tool: (1) Criteria selection, (2) Scoring definition, (3) Weighting of price criterion, (4) Definition of cut-off point for price criterion, (5) Ranking and weighting of remaining criteria. All consensus judgments were imported to the decision tool which can later be used in the real-world situation in the hospitals to support the selection and document the underlying rationale. The final list of criteria differs from the previously suggested international template and now reflects the Thai decision priorities and current decision processes. In the book chapter, the resulting model will be presented and a pathway for implementation will be discussed.
- 11 March 2020
- Published by IntechOpen
Open AccessWeighing Price and Performance for Decisions for Multisource Pharmaceutical Bidding in Public Hospitals in Thailand
Following a national law introduced in 2017 in Thailand, the selection of winning bidders for multisourced pharmaceuticals and medical supplies in public hospitals must reflect “price-performance” aligned with the principles of worthiness, transparency, efficiency, effectiveness and accountability. We describe how a practical tool using Multiple Criteria Decision Analysis (MCDA) for evidence-based decision making in hospital bidding (tender) was developed through a multi-stakeholder workshop format. The local leader of the initiative together with 2 international advisors guided the 37 workshop participants through five interactive steps for local adaptation of the previously developed and validated global MCDA-tool: (1) Criteria selection, (2) Scoring definition, (3) Weighting of price criterion, (4) Definition of cut-off point for price criterion, (5) Ranking and weighting of remaining criteria. All consensus judgments were imported to the decision tool which can later be used in the real-world situation in the hospitals to support the selection and document the underlying rationale. The final list of criteria differs from the previously suggested international template and now reflects the Thai decision priorities and current decision processes. In the book chapter, the resulting model will be presented and a pathway for implementation will be discussed.
- Open Access
- 29 December 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1003
Development of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences in their equivalence, manufacturing quality standards and reliability of supply. This necessitates reconsideration of the lowest price policy objective in pharmaceutical decision making. The aim of this study was to develop a Multi-Criteria Decision Analysis (MCDA) framework through a pilot workshop to inform the national procurement of OPPs in Indonesia. An initial list of potentially relevant criteria was identified based on previous work and a literature review. In a 2-day pilot policy workshop, twenty local experts representing different stakeholder groups and decision-making bodies selected the final criteria, approved the scoring function for each criterion, and assigned weights to each criterion. An MCDA framework was proposed for OPP drug decision making in developing countries, which included price and 8 non-price criteria. Based on the pilot policy workshop 6 + 1 criteria were considered relevant for Indonesia: pharmaceutical price (40% weight), manufacturing quality (18.8%), equivalence with the reference product (12.2%), product stability and drug formulation (12.2%), reliability of drug supply (8.4%), real world clinical or economic outcomes, such as adherence or non-drug costs (4.2%) and pharmacovigilance (3.6%). According to the pilot policy workshop, other criteria apart from price need to be strengthened in the tendering process. The introduction of additional criteria for OPP procurement in an MCDA framework creates incentives for manufacturers to invest into improved manufacturing standards, equivalence proof, product quality, reliability of supply or even additional real-world data collection, which ultimately may result in more health gain for the society.
- 29 December 2018
- Published by Springer Nature in BMC Health Services Research
- Vol. 18 (1) , 1003
Open AccessDevelopment of multi-criteria decision analysis (MCDA) framework for off-patent pharmaceuticals – an application on improving tender decision making in Indonesia
Off-patent pharmaceuticals (OPPs) hold vital importance in meeting public health objectives, especially in developing countries where resources are limited. OPPs are comprised of off-patent originals, branded generics and unbranded generics; nonetheless, these products are not identical and often there are differences in their equivalence, manufacturing quality standards and reliability of supply. This necessitates reconsideration of the lowest price policy objective in pharmaceutical decision making. The aim of this study was to develop a Multi-Criteria Decision Analysis (MCDA) framework through a pilot workshop to inform the national procurement of OPPs in Indonesia. An initial list of potentially relevant criteria was identified based on previous work and a literature review. In a 2-day pilot policy workshop, twenty local experts representing different stakeholder groups and decision-making bodies selected the final criteria, approved the scoring function for each criterion, and assigned weights to each criterion. An MCDA framework was proposed for OPP drug decision making in developing countries, which included price and 8 non-price criteria. Based on the pilot policy workshop 6 + 1 criteria were considered relevant for Indonesia: pharmaceutical price (40% weight), manufacturing quality (18.8%), equivalence with the reference product (12.2%), product stability and drug formulation (12.2%), reliability of drug supply (8.4%), real world clinical or economic outcomes, such as adherence or non-drug costs (4.2%) and pharmacovigilance (3.6%). According to the pilot policy workshop, other criteria apart from price need to be strengthened in the tendering process. The introduction of additional criteria for OPP procurement in an MCDA framework creates incentives for manufacturers to invest into improved manufacturing standards, equivalence proof, product quality, reliability of supply or even additional real-world data collection, which ultimately may result in more health gain for the society.
- Open Access
- 4 August 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (9) , 1333-1355
A Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
Chronic inflammatory diseases (CIDs) represent a substantial clinical and economic burden to patients, providers, payers and society overall. Biologics, such as tumor necrosis factor inhibitors (TNFi), have emerged as effective treatment options for patients with CIDs. However, the therapeutic potential of biologics is not always achieved in clinical practice, with results from studies examining the use of biologics in real-world settings suggesting lower levels of treatment effectiveness compared with clinical trial results. Using a targeted approach, this literature review demonstrates that compliance and persistence with biologic therapy is suboptimal and that this has implications for both clinical outcomes and treatment costs. The review identified a variety of predictors of treatment compliance and persistence, including increased age, female gender, presence of comorbidities, increased disease activity, longer disease duration, smoking, increased body mass index, higher biologic treatment dose, higher treatment cost and lower health-related quality-of-life scores. Patients often cited factors associated with medication delivery as a reason for non-compliance and non-persistence, and device-related improvements to treatment delivery were associated with higher rates of compliance and persistence. The articles identified in this review provide insights that have the potential to help guide the development of new solutions to improve disease management and optimize treatment regimens. This has the potential to benefit patients’ health by improving clinical outcomes and to reduce the burden to society by limiting the economic impact of patients’ disease. Funding UCB Pharma.
- 4 August 2018
- Published by Springer Nature in Advances in Therapy
- Vol. 35 (9) , 1333-1355
Open AccessA Targeted Literature Review Examining Biologic Therapy Compliance and Persistence in Chronic Inflammatory Diseases to Identify the Associated Unmet Needs, Driving Factors, and Consequences
Chronic inflammatory diseases (CIDs) represent a substantial clinical and economic burden to patients, providers, payers and society overall. Biologics, such as tumor necrosis factor inhibitors (TNFi), have emerged as effective treatment options for patients with CIDs. However, the therapeutic potential of biologics is not always achieved in clinical practice, with results from studies examining the use of biologics in real-world settings suggesting lower levels of treatment effectiveness compared with clinical trial results. Using a targeted approach, this literature review demonstrates that compliance and persistence with biologic therapy is suboptimal and that this has implications for both clinical outcomes and treatment costs. The review identified a variety of predictors of treatment compliance and persistence, including increased age, female gender, presence of comorbidities, increased disease activity, longer disease duration, smoking, increased body mass index, higher biologic treatment dose, higher treatment cost and lower health-related quality-of-life scores. Patients often cited factors associated with medication delivery as a reason for non-compliance and non-persistence, and device-related improvements to treatment delivery were associated with higher rates of compliance and persistence. The articles identified in this review provide insights that have the potential to help guide the development of new solutions to improve disease management and optimize treatment regimens. This has the potential to benefit patients’ health by improving clinical outcomes and to reduce the burden to society by limiting the economic impact of patients’ disease. Funding UCB Pharma.
- Open Access
- 1 March 2018
- Published by Elsevier in Journal of Bone Oncology
- Vol. 10, 49-56
Healthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
- 1 March 2018
- Published by Elsevier in Journal of Bone Oncology
- Vol. 10, 49-56
Open AccessHealthcare-resource utilization associated with radiation to bone across eight European countries: Results from a retrospective study
- Open Access
- 9 January 2018
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 4 (2) , 81-90
Systematic review of the cost-effectiveness of transcatheter interventions for valvular heart disease
Transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve repair (TMVR) are increasingly used for managing patients with valvular heart disease to whom surgery presents a high-risk. As these are costly procedures, a systematic review of studies concerned with their economic assessment was undertaken. The search was performed in PubMed and the Cochrane Library and followed recommended methodological steps. Studies were screened and their data were retrieved and were synthesized using a narrative approach. Twenty-four, good to high quality, evaluations were identified, representing different viewpoints, modelling techniques and willingness-to-pay thresholds. Studies show that in high-risk patients with symptomatic aortic stenosis, TAVI may be cost-effective compared with medical management (MM) across many health care settings. In contrast, studies of TAVI compared with surgical aortic valve replacement (SAVR) yield conflicting and inconclusive results. The limited data available show that TMVR may also be cost-effective relative to MM in mitral valve disease. Existing evidence indicates that transcatheter techniques may be cost-effective options, relative to MM, in high-risk patients with valvular disease. Nonetheless, more research is needed to establish their economic value further, to investigate the drives of cost-effectiveness, and to evaluate surgical with transcatheter techniques in aortic valvular disease.
- 9 January 2018
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 4 (2) , 81-90
Open AccessSystematic review of the cost-effectiveness of transcatheter interventions for valvular heart disease
Transcatheter aortic valve implantation (TAVI) and transcatheter mitral valve repair (TMVR) are increasingly used for managing patients with valvular heart disease to whom surgery presents a high-risk. As these are costly procedures, a systematic review of studies concerned with their economic assessment was undertaken. The search was performed in PubMed and the Cochrane Library and followed recommended methodological steps. Studies were screened and their data were retrieved and were synthesized using a narrative approach. Twenty-four, good to high quality, evaluations were identified, representing different viewpoints, modelling techniques and willingness-to-pay thresholds. Studies show that in high-risk patients with symptomatic aortic stenosis, TAVI may be cost-effective compared with medical management (MM) across many health care settings. In contrast, studies of TAVI compared with surgical aortic valve replacement (SAVR) yield conflicting and inconclusive results. The limited data available show that TMVR may also be cost-effective relative to MM in mitral valve disease. Existing evidence indicates that transcatheter techniques may be cost-effective options, relative to MM, in high-risk patients with valvular disease. Nonetheless, more research is needed to establish their economic value further, to investigate the drives of cost-effectiveness, and to evaluate surgical with transcatheter techniques in aortic valvular disease.
- 1 January 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (1) , 67-77
Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
Objective The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy in Greece. Methods The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime. Clinical data were retrieved from a head-to-head clinical trial (DURATION 3) and a published network meta-analysis comparing ExQW with IG or Lira1.2mg, respectively. Following a Greek third-party payer perspective, direct medical costs related to drug acquisition, consumables, developed micro- and macrovascular complications, maintenance treatment, as well as treatment-related adverse events were considered. Cost and utility data were extracted from literature and publicly available official sources and assigned to model parameters to calculate total quality-adjusted life-years (QALYs) and total costs as well as incremental cost-effectiveness ratios (ICERs). Sensitivity analyses explored the impact of changes in input data. Results Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of a, (sic)2061 or a, (sic)110, respectively. The ICER for ExQW was a, (sic)4499/QALY compared with IG and a, (sic)2827/QALY compared with Lira1.2mg. Results were robust across various one-way and scenario analyses. At the defined willingness-to-pay threshold of a, (sic)36,000/QALY, probabilistic sensitivity analysis showed that ExQW had a 100 or 88.2% probability of being cost effective relative to IG or Lira1.2mg, respectively. Conclusion ExQW was estimated to be cost effective relative to IG or Lira1.2mg for the treatment of T2DM in adults not adequately controlled on OAD therapy in Greece.
- 1 January 2018
- Published by Springer Nature in Clinical Drug Investigation
- Vol. 38 (1) , 67-77
Cost Effectiveness of Exenatide Once Weekly Versus Insulin Glargine and Liraglutide for the Treatment of Type 2 Diabetes Mellitus in Greece
Objective The objective of this study was to evaluate the long-term cost effectiveness of exenatide once weekly (ExQW) versus insulin glargine (IG) or liraglutide 1.2 mg (Lira1.2mg) for the treatment of adult patients with type 2 diabetes mellitus (T2DM) not adequately controlled on oral antidiabetic drug (OAD) therapy in Greece. Methods The published and validated Cardiff Diabetes Model was used to project clinical and economic outcomes over a patient's lifetime. Clinical data were retrieved from a head-to-head clinical trial (DURATION 3) and a published network meta-analysis comparing ExQW with IG or Lira1.2mg, respectively. Following a Greek third-party payer perspective, direct medical costs related to drug acquisition, consumables, developed micro- and macrovascular complications, maintenance treatment, as well as treatment-related adverse events were considered. Cost and utility data were extracted from literature and publicly available official sources and assigned to model parameters to calculate total quality-adjusted life-years (QALYs) and total costs as well as incremental cost-effectiveness ratios (ICERs). Sensitivity analyses explored the impact of changes in input data. Results Over a patient's lifetime, ExQW was associated with 0.458 or 0.039 incremental QALYs compared with IG or Lira1.2mg, respectively, at additional costs of a, (sic)2061 or a, (sic)110, respectively. The ICER for ExQW was a, (sic)4499/QALY compared with IG and a, (sic)2827/QALY compared with Lira1.2mg. Results were robust across various one-way and scenario analyses. At the defined willingness-to-pay threshold of a, (sic)36,000/QALY, probabilistic sensitivity analysis showed that ExQW had a 100 or 88.2% probability of being cost effective relative to IG or Lira1.2mg, respectively. Conclusion ExQW was estimated to be cost effective relative to IG or Lira1.2mg for the treatment of T2DM in adults not adequately controlled on OAD therapy in Greece.
- 1 September 2016
- Published by Elsevier in Resuscitation
- Vol. 106, e38
Nursing staff's theoretical knowledge of cardiovascular resuscitation in Greece
- 1 September 2016
- Published by Elsevier in Resuscitation
- Vol. 106, e38
Nursing staff's theoretical knowledge of cardiovascular resuscitation in Greece
- Open Access
- 14 April 2016
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 14 (1) , 1-9
Cost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting. A Markov model was adapted to compare the use of ranibizumab 0.5 mg (pro re nata-PRN and treat and extend-T&E) to aflibercept 2 mg (every 8 weeks after five initial doses) in DME. Patients transitioned at a 3-month cycle among nine specified health states (including death) over a lifetime horizon. Transition probabilities, utilities, as well as DME-related mortality were extracted from relevant clinical trials, a network meta-analysis and other published studies. The analysis was conducted from payer perspective and as such only costs reimbursed by the payer were considered (year 2014). The incremental cost per quality-adjusted life year (QALY) gained and the net monetary benefit was the main outcome measures. Τhe use of PRN and T&E ranibizumab regimens were shown to be cost saving comparing to aflibercept (by €2824 and €22, respectively), and more beneficial in terms of QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted in a net monetary benefit of €3984 and €1278, respectively. Both PRN and T&E ranibizumab regimens were more beneficial and less costly compared to aflibercept for the management of DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual impairment due to DME in the Greek setting.
- 14 April 2016
- Published by Springer Nature in Cost Effectiveness and Resource Allocation
- Vol. 14 (1) , 1-9
Open AccessCost-utility of ranibizumab versus aflibercept for treating Greek patients with visual impairment due to diabetic macular edema
To conduct a cost-utility analysis of ranibizumab versus aflibercept for the treatment of patients with visual impairment due to diabetic macular edema (DME) in the Greek setting. A Markov model was adapted to compare the use of ranibizumab 0.5 mg (pro re nata-PRN and treat and extend-T&E) to aflibercept 2 mg (every 8 weeks after five initial doses) in DME. Patients transitioned at a 3-month cycle among nine specified health states (including death) over a lifetime horizon. Transition probabilities, utilities, as well as DME-related mortality were extracted from relevant clinical trials, a network meta-analysis and other published studies. The analysis was conducted from payer perspective and as such only costs reimbursed by the payer were considered (year 2014). The incremental cost per quality-adjusted life year (QALY) gained and the net monetary benefit was the main outcome measures. Τhe use of PRN and T&E ranibizumab regimens were shown to be cost saving comparing to aflibercept (by €2824 and €22, respectively), and more beneficial in terms of QALYs gained (+0.05) and time without visual impairment (0.031 and 0.034 years), thereby dominating aflibercept. Moreover, ranibizumab used as PRN or T&E resulted in a net monetary benefit of €3984 and €1278, respectively. Both PRN and T&E ranibizumab regimens were more beneficial and less costly compared to aflibercept for the management of DME. Hence, ranibizumab seems to be a dominant option for the treatment of visual impairment due to DME in the Greek setting.
- Open Access
- 4 December 2015
- Published by International Cardiovascular Forum Journal in International Cardiovascular Forum Journal
- Vol. 4, 43-52
Economic Evaluation of Cardiac Contractility Modulation (CCM) Therapy with the Optimizer IVs in the Management of Heart Failure Patients
Background: Heart failure represents a major burden for health systems and societies. Cardiac contractility modulation (CCM) therapy was developed in recent years for patients with normal QRS in whom optimal pharmacological (OMT) treatment has failed to control symptoms adequately. This study presents an economic evaluation of CCM therapy for the UK. Methods: A Markov model was built to simulate the management of patients under two therapy scenarios, on OMT alone and CCM+OMT respectively. The horizon is the patient’s life time and the cycle is 4 weeks. The model estimates life year (LYs), quality adjusted life years (QALYs) and overall treatment costs. Data to populate it came from relevant CCM trials, the literature and other sources. Results: The total mean life-time cost was £37,467 in the CCM+OMT arm and £16,885 in the OMT arm. Patients in the OMT arm gained 7.00 LYs and 4.00 QALYs and those on CCM+OMT 7.96 and 5.26 respectively. The incremental cost per QALY was £16,405and the incremental cost per LY £21,415. Sensitivity analysis indicates that the results are pretty stable and stochastic analysis indicates that at a £30,000 per QALY threshold the likelihood of CCM+OMT being cost-effective is 99.8% and at £25,000 per QALY 97%. Conclusion: The present analysis indicates that CCM may be cost-effective therapy. This early conclusion should be viewed in the light of the caveats of the modeling methods used, due to data availability. Long-term studies directly collecting hospitalization and mortality data should be undertaken to provide more robust evidence.
- 4 December 2015
- Published by International Cardiovascular Forum Journal in International Cardiovascular Forum Journal
- Vol. 4, 43-52
Open AccessEconomic Evaluation of Cardiac Contractility Modulation (CCM) Therapy with the Optimizer IVs in the Management of Heart Failure Patients
Background: Heart failure represents a major burden for health systems and societies. Cardiac contractility modulation (CCM) therapy was developed in recent years for patients with normal QRS in whom optimal pharmacological (OMT) treatment has failed to control symptoms adequately. This study presents an economic evaluation of CCM therapy for the UK. Methods: A Markov model was built to simulate the management of patients under two therapy scenarios, on OMT alone and CCM+OMT respectively. The horizon is the patient’s life time and the cycle is 4 weeks. The model estimates life year (LYs), quality adjusted life years (QALYs) and overall treatment costs. Data to populate it came from relevant CCM trials, the literature and other sources. Results: The total mean life-time cost was £37,467 in the CCM+OMT arm and £16,885 in the OMT arm. Patients in the OMT arm gained 7.00 LYs and 4.00 QALYs and those on CCM+OMT 7.96 and 5.26 respectively. The incremental cost per QALY was £16,405and the incremental cost per LY £21,415. Sensitivity analysis indicates that the results are pretty stable and stochastic analysis indicates that at a £30,000 per QALY threshold the likelihood of CCM+OMT being cost-effective is 99.8% and at £25,000 per QALY 97%. Conclusion: The present analysis indicates that CCM may be cost-effective therapy. This early conclusion should be viewed in the light of the caveats of the modeling methods used, due to data availability. Long-term studies directly collecting hospitalization and mortality data should be undertaken to provide more robust evidence.
- Open Access
- 23 September 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 2 (1) , 6-15
The European Society of Cardiology Atlas of Cardiology: rational, objectives, and methods
The need to develop better policies for increasing the efficiency and effectiveness of cardiac care and for reducing the burden of cardiovascular disease, necessitates the availability of data on the economic, political, and organizational aspects of cardiac care. The European Society of Cardiology has this started collecting such data together with the National Cardiac Societies from across Europe. In particular, descriptive and quantitative data concerning the economy, demographics, socioeconomics, health status, health system, and health policies are gathered for every single member country of the European Society of Cardiology, alongside data concerning the number of cardiac care physicians, hospitals, beds, laboratories, interventions, and reimbursement figures. These data will be helpful in an effort to understand in more depth the dynamics of healthcare systems from a cardiology perspective and to identify trends, disparities, gaps, and best practice models, all of which will be useful for making recommendations to improve decision and policy making concerning the cardiac care field at national and cross national level.
- 23 September 2015
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 2 (1) , 6-15
Open AccessThe European Society of Cardiology Atlas of Cardiology: rational, objectives, and methods
The need to develop better policies for increasing the efficiency and effectiveness of cardiac care and for reducing the burden of cardiovascular disease, necessitates the availability of data on the economic, political, and organizational aspects of cardiac care. The European Society of Cardiology has this started collecting such data together with the National Cardiac Societies from across Europe. In particular, descriptive and quantitative data concerning the economy, demographics, socioeconomics, health status, health system, and health policies are gathered for every single member country of the European Society of Cardiology, alongside data concerning the number of cardiac care physicians, hospitals, beds, laboratories, interventions, and reimbursement figures. These data will be helpful in an effort to understand in more depth the dynamics of healthcare systems from a cardiology perspective and to identify trends, disparities, gaps, and best practice models, all of which will be useful for making recommendations to improve decision and policy making concerning the cardiac care field at national and cross national level.